Mandatory Human Abuse Liability Assessment Gains Role in Drug Scheduling and Regulatory Compliance

A recent analysis of the Mandatory Human Abuse Liability Assessment (MAHA) has highlighted its potential implications for drug development and regulatory processes. The MAHA, which evaluates the abuse potential of certain drugs, is gaining attention as a critical tool in determining how substances are classified and monitored under federal law. The assessment’s findings could influence decisions regarding labeling, marketing restrictions, and post-market surveillance requirements for pharmaceutical products.

The MAHA process involves rigorous testing to identify whether a drug has characteristics that may lead to misuse or dependency. This evaluation typically includes clinical studies comparing the drug’s effects to known substances with abuse potential. Regulatory agencies use these results to inform their decisions on scheduling under the Controlled Substances Act and other measures aimed at minimizing public health risks. Industry stakeholders are closely monitoring developments related to MAHA assessments, as they may impact timelines for product approval and introduce additional compliance obligations for manufacturers.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Author

Mark Chiang